Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

6 May 2014

RDT receives FDA approval for new liquid form of treatment for patients with ALL

Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension---a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).

30 Apr 2014

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has entered into a license agreement with Intravacc (Institute for Translational Vaccinology) from The Netherlands to develop and commercialize the Sabin Inactivated Polio Vaccine (sIPV) for distribution to China and other countries.

28 Apr 2014

Oral health: The gateway to your overall health

If the eyes are the windows to your soul, then your mouth is the gateway to your overall health. Research has found a surprising number of links between the state of your oral health and your overall health.

25 Apr 2014

New Ebola variant identified in Guinea

Performed in less than a month, sequencing of the complete genome and subsequent phylogenetic analysis show that the virus present in Guinea forms a clade (variant) that is distinct from strains previously identified in the Democratic Republic of Congo and in Gabon. Epidemiological investigations also linked the laboratory confirmed cases with the initial deaths recorded during the December 2013 outbreak.

25 Apr 2014

Enhanced recovery approach used for colorectal surgery cut hospital stays

Changes in managing patients before, during and after colorectal surgery cut hospital stays by two days and reduced readmission rates, according to researchers who led a study of the approach at Duke University Hospital.

25 Apr 2014

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.

23 Apr 2014

Nocturnal incontinence poses major burden after female bladder reconstruction

Health-related quality of life is lower in women who have undergone radical cystectomy and neobladder reconstruction for bladder cancer than in the general female population, shows research.

22 Apr 2014

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Baxter International Inc. today announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of BAX 111. BAX 111 is a recombinant von Willebrand factor (rVWF) under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder.

From Baxter International Inc. 16 Apr 2014

Scientists to combine environmental, surveillance data to predict malaria outbreaks in Ethiopia

Dealing with malaria is a fact of life for more than 91 million Ethiopians. Each year four to five million contract malaria, one of the biggest health problems in this poor country.

16 Apr 2014

Prestige Brands Holdings signs agreement for acquisition of Hydralyte

Prestige Brands Holdings, Inc. today announced the signing of a purchase agreement for the acquisition of Hydralyte in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia. The acquisition is expected to close, subject to customary closing conditions, during the first quarter of fiscal 2015, which began on April 1, 2014.

15 Apr 2014

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Phase I study findings suggest the investigational drug ceritinib is effective in patients with advanced non-small-cell lung cancer with anaplastic lymphoma kinase gene rearrangement, even in those who develop resistance to crizotinib.

14 Apr 2014

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza.

11 Apr 2014

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc.

8 Apr 2014

Study: Indoor tanning may be marker of eating disorder-related behaviors

High school students who use indoor tanning also have higher rates of unhealthy weight control behaviors-such as taking diet pills or vomiting to lose weight, reports a study in the April Journal of Developmental & Behavioral Pediatrics, the official journal of the Society for Developmental and Behavioral Pediatrics.

7 Apr 2014

Frail elderly people are at increased risk of death from outbreaks of viral gastroenteritis

Frail elderly people living in residential care facilities are at increased risk of severe illness or death from outbreaks of viral gastroenteritis.

3 Apr 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Pacira Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL (bupivacaine liposome injectable suspension). The suite is housed at the company's Science Center Campus in San Diego, where EXPAREL is currently manufactured.

31 Mar 2014

Longer looks: Exercise to treat depression; crowdsourcing treatment decisions; nitroglycerin shortage

Depression is the most common mental illness - affecting a staggering 25 percent of Americans - but a growing body of research suggests that one of its best cures is cheap and ubiquitous.

28 Mar 2014

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven months in adults with advanced anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who received 400 mg or higher of LDK378 per day.

28 Mar 2014

Vomiting News and Research

Further Reading

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

RDT receives FDA approval for new liquid form of treatment for patients with ALL

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Oral health: The gateway to your overall health

New Ebola variant identified in Guinea

Enhanced recovery approach used for colorectal surgery cut hospital stays

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Nocturnal incontinence poses major burden after female bladder reconstruction

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Scientists to combine environmental, surveillance data to predict malaria outbreaks in Ethiopia

Prestige Brands Holdings signs agreement for acquisition of Hydralyte

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Study: Indoor tanning may be marker of eating disorder-related behaviors

Frail elderly people are at increased risk of death from outbreaks of viral gastroenteritis

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Longer looks: Exercise to treat depression; crowdsourcing treatment decisions; nitroglycerin shortage

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News